title: [Effects of parathyroid hormone (teriparatide) on bone mass and quality in osteoporosis].
abstract: Parathyroid hormone (PTH) acts as an anabolic agent and is used for the treatment for osteoporosis. Daily or once-weekly self-administered subcutaneous injection of human PTH(1-34) (teriparatide) increased bone mineral density (BMD) compared to a placebo in post-menopausal osteoporotic patients. Recently, data have accumulated that collagen cross-link formation in bone affect bone strength. In fact, impaired enzymatic cross-linking and/or an increase in non-enzymatic cross-links, pentosidine, which is a surrogate marker of advanced glycation end products(AGEs), in bone collagen have been proposed as a major cause of bone fragility in osteoporosis. Teriparatide improves bone collagen cross-link formation, microarchitecture, and bone mass, resulting in the increase of bone strength.
authors.affiliation: Department of Orthopaedic Surgery, The Jikei University School of Medicine.
authors.forename: Keishi
authors.initials: K
authors.lastname: Marumo
authors.forename: Mitsuru
authors.initials: M
authors.lastname: Saito
mesh_terms: D000368:Aged; D015519:Bone Density / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010024:Osteoporosis / Q000188:drug therapy*; D019379:Teriparatide / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D050071:Bone Density Conservation Agents; D019379:Teriparatide